I guess it could be worse as we could be $50 a share right now.
Frustrated, I can understand the frustrations of you and anyone else that does not like the current share price, though I think you are missing the long term picture of buy-out scenarios. You do realize that any biotech with a stealth pipeline eventually, usually gets bought out. Prior to Fargo and leading up to the pps rising above $5 on "NO NEWS" was just the beginning and I agree with you, that the current price right now (minus Fargo being revealed) could likely be $50 pps!
Here is the trouble and the problem of those days. We know now that the likely partner was about to be "Abbvie" and what we don't know are the terms of the partnership. Again, SK never mentioned "collaborations" until after they discovered a much better understanding of PS Targeting and how its synergistic properties with much, if not many... if not all medical treatment. Of course some more effective than others... but the bottom line is PS Targeting allows other treatments to be covered under a new patent for many more years of profits.
Anyhow, I believe the deal had changed with Abbvie, actually... Peregrine now seemingly has the upper hand in deal making and some Big Pharma are simply not used to that. They (Big Pharma) are used to sitting at the table and spreading crumbs here and there, along with being forced to take a BOD or two.... and eventually, that current $50 pps you were talking about would then place a premium on top of for that eventual buyout. That price? Who knows.... $75... $100... $125..."UNDER" the old Abbvie agreement.
Things are changed for the better and the quicker that some BP's realize the potential of PS Targeting and the potential that their competitors may be granted, the quicker our pps starts to rise to $5+, just as it did back in Sept 2012. The difference being, future partnerships/collaborations will be structured in a "pro" Peregrine way, where buyouts of $75 ... $100 ... or $125 will not even be considered!
The game has changed. The PS Targeting MOA is better understood.
PS Targeting will be in the hands of hundreds with royalties spread out far and wide and not one single BP will take advantage of controlling it in my view.
Flipped-PS exists in humans, plants and animals.
A buyout what was once thought of, geared mainly towards human disease is like black/white TV in the 50's..... we are talking Bavi crops, Veterinary medical uses, dogs living longer, humans healing faster than ever before, increased NASA research (bone density loss in space was the #1 problem, along with radiation and the damage it causes), extraction from plants for certain uses such as biofuel that can already be used in gasoline engines is not out of the question, high density plastics (NASA researches that as well.... and the list goes on and on, because of the better understanding of the MOA of PS Targeting.
Say good bye to $75... $100... or $125 buyouts.
The stakes have risen and the BP's will rise, after they fall to their knees and ask Peregrine nicely to bargain again. Lets hope they make some good-faith offers, or else..... its PS Targeting being licensed by Peregrine to many ... many.. many people, businesses, universities, non-profits, for-profits, small biotech and some BP's.
The difficult part is the current stock price, but I'd much rather be in this situation, knowing that future partnerships/collaborations are structured in a way that maximizes shareholder value in the longterm. That is what SK and Peregrine will be accomplishing.
So maybe... just maybe... shares will be on sale tomorrow morning at 9:30 for $1.63, limited time only : )
News 
Market Data 
Discover 
AI
